GT200600315A - Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida - Google Patents

Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Info

Publication number
GT200600315A
GT200600315A GT200600315A GT200600315A GT200600315A GT 200600315 A GT200600315 A GT 200600315A GT 200600315 A GT200600315 A GT 200600315A GT 200600315 A GT200600315 A GT 200600315A GT 200600315 A GT200600315 A GT 200600315A
Authority
GT
Guatemala
Prior art keywords
ilo
methyl
iloamino
pirimidina
trifluorometilo
Prior art date
Application number
GT200600315A
Other languages
English (en)
Spanish (es)
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600315A publication Critical patent/GT200600315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GT200600315A 2005-07-20 2006-07-14 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida GT200600315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
GT200600315A true GT200600315A (es) 2007-03-19

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600315A GT200600315A (es) 2005-07-20 2006-07-14 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Country Status (42)

Country Link
US (4) US8343984B2 (enExample)
EP (5) EP2284167B2 (enExample)
JP (3) JP5289948B2 (enExample)
KR (3) KR101651288B1 (enExample)
CN (2) CN103804356A (enExample)
AR (1) AR054846A1 (enExample)
AU (3) AU2006276204A1 (enExample)
BR (1) BRPI0613615B1 (enExample)
CA (1) CA2614334C (enExample)
CR (1) CR9657A (enExample)
CU (1) CU23916B1 (enExample)
CY (2) CY1113076T1 (enExample)
DK (2) DK2284167T4 (enExample)
EA (2) EA016856B1 (enExample)
EC (1) ECSP088119A (enExample)
ES (3) ES2623608T5 (enExample)
GE (1) GEP20115302B (enExample)
GT (1) GT200600315A (enExample)
HN (1) HN2008000311A (enExample)
HR (2) HRP20120573T1 (enExample)
HU (1) HUE031791T2 (enExample)
IL (2) IL188189A0 (enExample)
JO (1) JO3308B1 (enExample)
LT (1) LT2284167T (enExample)
MA (1) MA29626B1 (enExample)
MX (1) MX2008000899A (enExample)
MY (1) MY148554A (enExample)
NI (1) NI200800017A (enExample)
NO (1) NO341930B1 (enExample)
NZ (1) NZ564409A (enExample)
PE (1) PE20070214A1 (enExample)
PH (1) PH12013501590A1 (enExample)
PL (2) PL1912973T3 (enExample)
PT (2) PT1912973E (enExample)
RS (1) RS55929B2 (enExample)
SG (1) SG163620A1 (enExample)
SI (2) SI2284167T2 (enExample)
SM (1) SMP200800011B (enExample)
TN (1) TNSN08029A1 (enExample)
TW (1) TWI406661B (enExample)
UA (1) UA94234C2 (enExample)
WO (1) WO2007015870A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CN101415426A (zh) * 2006-04-07 2009-04-22 诺瓦提斯公司 c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
JP2011507880A (ja) 2007-12-21 2011-03-10 ノバルティス アーゲー 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) * 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
BRPI1013366A2 (pt) 2009-03-06 2016-03-29 Novartis Ag uso de derivados de pirimidilaminobenzamida para o tratamento de distúrbios mediados pela quinase contendo zíper de leucina e quinase contendo motivo alfa estéril (zak).
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
RU2012120901A (ru) 2009-10-23 2013-12-10 Новартис Аг Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (en) * 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
EP2571863B1 (en) 2010-06-21 2015-09-23 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (en) * 2010-11-26 2012-05-31 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2014532647A (ja) 2011-10-28 2014-12-08 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
PE20141337A1 (es) 2011-11-14 2014-10-16 Novartis Ag Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
AU2013289175A1 (en) 2012-07-11 2015-01-22 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2906554A4 (en) * 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP2958916B1 (en) * 2013-02-21 2018-09-12 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
BR112015026827A2 (pt) 2013-04-24 2017-09-05 Dr Reddy´S Laboratories Ltd Formas polimórficas de cloridrato de nilotinibe
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
US10016423B2 (en) * 2014-10-16 2018-07-10 Apotex Inc. Solid forms of nilotinib hydrochloride
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
HUE050890T2 (hu) 2016-03-14 2021-01-28 Pliva Hrvatska D O O Nilotinib sók szilárd halmazállapotú formái
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
EP3806858A4 (en) * 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
US12065426B2 (en) 2018-11-05 2024-08-20 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
JP2023513045A (ja) 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
EP4355306A1 (en) 2021-06-19 2024-04-24 Helm AG Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
CN113788817A (zh) * 2021-09-27 2021-12-14 南京海润医药有限公司 一种尼罗替尼半盐酸盐一水合物晶型及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CN1882344A (zh) * 2003-11-18 2006-12-20 诺瓦提斯公司 Kit突变形式的抑制剂
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
US20130165465A1 (en) 2013-06-27
HRP20170634T4 (hr) 2020-02-07
MY148554A (en) 2013-04-30
KR20080027853A (ko) 2008-03-28
BRPI0613615B1 (pt) 2022-02-08
SG163620A1 (en) 2010-08-30
JP5289948B2 (ja) 2013-09-11
PL2284167T5 (pl) 2020-07-27
KR101651288B1 (ko) 2016-08-25
AR054846A1 (es) 2007-07-18
EP2284168A3 (en) 2011-04-13
AU2011202047A1 (en) 2011-05-26
PL2284167T3 (pl) 2017-07-31
CR9657A (es) 2008-04-16
UA94234C2 (uk) 2011-04-26
JP2014221831A (ja) 2014-11-27
DK2284167T4 (da) 2020-03-02
EP2535337B1 (en) 2017-08-23
ECSP088119A (es) 2008-02-20
JP5798101B2 (ja) 2015-10-21
NO341930B1 (no) 2018-02-19
EA016856B1 (ru) 2012-08-30
TNSN08029A1 (en) 2009-07-14
AU2012201453A1 (en) 2012-04-05
HRP20120573T1 (hr) 2012-08-31
DK2284167T3 (en) 2017-05-01
JP2013018789A (ja) 2013-01-31
ES2386974T3 (es) 2012-09-10
CN102358736A (zh) 2012-02-22
EP2543665A3 (en) 2013-05-29
CU23916B1 (es) 2013-07-31
PT1912973E (pt) 2012-09-03
KR20130077915A (ko) 2013-07-09
ES2623608T3 (es) 2017-07-11
WO2007015870A3 (en) 2007-06-07
EP2284167A3 (en) 2011-03-02
NO20080820L (no) 2008-04-15
TWI406661B (zh) 2013-09-01
SMAP200800011A (it) 2008-02-27
ES2648288T3 (es) 2017-12-29
TW200740793A (en) 2007-11-01
WO2007015870A2 (en) 2007-02-08
US8415363B2 (en) 2013-04-09
EA200800201A1 (ru) 2008-06-30
NI200800017A (es) 2009-03-03
RS55929B1 (sr) 2017-09-29
SMP200800011B (it) 2008-02-27
BRPI0613615A2 (pt) 2011-01-18
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
JP2009502795A (ja) 2009-01-29
US20140343087A1 (en) 2014-11-20
HUE031791T2 (en) 2017-08-28
CY1119624T1 (el) 2018-04-04
US20130023548A1 (en) 2013-01-24
JO3308B1 (ar) 2018-09-16
CU20080006A7 (es) 2011-02-24
KR20130085444A (ko) 2013-07-29
DK1912973T3 (da) 2012-07-23
EP2535337A1 (en) 2012-12-19
GEP20115302B (en) 2011-10-10
CA2614334C (en) 2015-04-21
SI2284167T2 (sl) 2020-03-31
EP2284167B2 (en) 2019-11-27
PH12013501590A1 (en) 2015-09-21
EP2543665A2 (en) 2013-01-09
EP2284167B1 (en) 2017-02-01
IL214659A0 (en) 2011-09-27
AU2012201453B2 (en) 2013-09-05
CA2614334A1 (en) 2007-02-08
PE20070214A1 (es) 2007-04-02
CY1113076T1 (el) 2016-04-13
HRP20170634T1 (hr) 2017-06-30
MA29626B1 (fr) 2008-07-01
NZ564409A (en) 2011-07-29
SI2284167T1 (sl) 2017-05-31
PT2284167T (pt) 2017-05-15
EP1912973A2 (en) 2008-04-23
EP2284168A2 (en) 2011-02-16
EA013464B1 (ru) 2010-04-30
HK1116783A1 (en) 2009-01-02
US8829015B2 (en) 2014-09-09
ES2623608T5 (es) 2020-06-18
SI1912973T1 (sl) 2012-08-31
LT2284167T (lt) 2017-04-25
EP1912973B1 (en) 2012-06-13
US20080269269A1 (en) 2008-10-30
US8343984B2 (en) 2013-01-01
HN2008000311A (es) 2011-01-24
RS55929B2 (sr) 2020-12-31
AU2006276204A1 (en) 2007-02-08
MX2008000899A (es) 2008-03-18
PL1912973T3 (pl) 2012-09-28
EP2284167A2 (en) 2011-02-16
IL188189A0 (en) 2008-03-20
EA201000145A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
GT200600315A (es) Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
UY29683A1 (es) Sales de 4-metil-n-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
HN2007000536A (es) Formas cristalinas
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
AR085903A1 (es) Compuestos de pirazol sustituidos con halogeno
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
MX2009011456A (es) Aumento de la productividad de las plantas por combinacion de agentes quimicos con modificaciones transgenicas.
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
EP1733480A4 (en) PERIODIC CALIBRATION FOR COMMUNICATION CHANNELS BY REFERRING UNDESIRABLE VARIATIONS
ECSP088369A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicóticos y neurodegenerativos
DE502005007669D1 (de) Aktuierungsmittel für eine crash-aktive kopfstütze
MA31985B1 (fr) (r)-2-(4-cyclopropanesulfonyl-phényl)-n-pyrazin-2-yl-3-(tétrahydropyran-4-yl)- propionamide cristallin
HN2009001436A (es) Nuevo procedimiento de sintesis de la agometatina
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
CY1116596T1 (el) Αλατα ισοφωσφοραμιδικης μουσταρδας και αναλογα αυτων
ECSP11011167A (es) Síntesis y formas de sales novedosas de (r) -5- ( (e) -2- (pirrolidin-3-ilvinil) pirimidina
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TW200640886A (en) Crystalline forms of linezolid intermediate
CY1109038T1 (el) Μη στεροειδεις ρυθμιστες υποδοχεα γλυκοκορτικοειδων
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
EP2183256A4 (en) THERAPEUTIC COMPOUNDS
PA8645401A1 (es) Procedimiento de fabricacion de compuestos imidazolicos, sus sales y sus pseudopolimorfos
BRPI0605917A2 (pt) intermediário cristalino de rosuvastatina